(Q55309836)

English

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. (English)

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

0 references

14

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

7

object named as

Luis Fayad

0 references

Michelle A Fanale

9

object named as

Michelle Fanale

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Sattva S Neelapu

10

object named as

Sattva Neelapu

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

6

object named as

Larry W Kwak

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Jorge Romaguera

3

object named as

Jorge Romaguera

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Fredrick B Hagemeister

8

object named as

Frederick Hagemeister

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

1

object named as

Anas Younes

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Amanda R Copeland

4

object named as

Amanda Copeland

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

author name string

Stella Kim

2

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Silvana de Castro Farial

5

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

John M Lambert

11

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Rodica Morariu-Zamfir

12

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Sandrine Payrard

13

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

language of work or name

0 references

publication date

2 July 2012

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Journal of Clinical Oncology

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

30

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

22

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

2776-2782

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Antibody conjugate therapeutics: challenges and potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Beyond chemotherapy: new agents for targeted treatment of lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Antibody-drug conjugates: targeted drug delivery for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

CD19: a promising B cell target for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Germinal center structure and function: lessons from CD19

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Semisynthetic maytansine analogues for the targeted treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

3 July 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

12 August 2018

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

12 August 2018

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950497

12 August 2018

Identifiers

10.1200/JCO.2011.39.4403

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

1 reference

Europe PubMed Central

1 July 2018

http://europepmc.org/abstract/PMC/5950497

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55309836&oldid=2138091975"